European Companies Search Engine
EU funding (€3,983,592): Organoids for Virus Research - An innovative training-ETN programme Hor12 Nov 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Organoids for Virus Research - An innovative training-ETN programme
OrganoVIR (Organoids for Virus Research) will train young researchers (ESRs) in the field of organoids and virology. Human viral infection studies lack suitable experimental models as animal models or conventional 2-dimensional (2D) cell cultures do not translate to human infection. OrganoVIR makes use of the breakthrough in the culturing of primary human cells into 3D cultures (organoids). Within this ETN programme, organoids will be used for the first time to study human viral infections in their natural environment. OrganoVIR includes leading partners in virology and organoid technology covering 7 academic institutes, 3 life science companies, 1 organoid technology private company, 2 non-profit organisations, a national public health institute and a business school originating from 8 countries. The aim is to introduce and establish human organoids as superior models for viral pathogenesis studies and antiviral testing, thus replacing animal models and reducing animal use. OrganoVIR provides a full package ETN programme for ESRs to learn the science of innovative 3D culture systems for virus research as well as financial, commercial, ethical, communicative, policy and dissemination aspects for optimal valorization. The projects are intensified by significant secondments at commercial, governmental and non-profit partner institutes. OrganoVIR provides: - High-ranked scientific and technical training in an interdisciplinary, intersectoral and international top research project - Training in transferrable managerial skills, including a pre-MBA - Implementation of innovative organoid technology for viral pathogenesis studies and antiviral development - Innovation in organoid technology by co-culture design and high throughput screening. OrganoVIR combines frontier research with an innovative training programme in a complementary network, certifying high impact scientists.
Funded Companies:
| Company name | Funding amount |
| EPITHELIX Sàrl | ? |
| ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM | €531,240 |
| CHARLES RIVER NEDERLAND B.V. | €265,620 |
| Danmarks Tekniske Universitet | €297,522 |
| Katholieke Universiteit Leuven | €768,960 |
| Stemcell Technologies UK Ltd. | €303,173 |
| Universite Clermont Auvergne | €549,604 |
| UNIVERSITE DE GENEVE | €281,277 |
| UNIVERSITEIT UTRECHT | €265,620 |
| UNIVERSITEIT VAN AMSTERDAM | €265,620 |
| Uniwersytet Jagiellonski | €454,957 |
Source: https://cordis.europa.eu/project/id/812673
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Epithelix Sàrl, Plan-les-Ouates, Switzerland.
The visualizations for "EPITHELIX Sàrl - EU funding (€3,983,592): Organoids for Virus Research - An innovative training-ETN programme"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
